
Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …

As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

